Pavmed INC 10-Q quarterly reports

PAVmed Inc. filed its Q2 2026 Form 10-Q, detailing continued operational losses, a significant increase in R&D expenses, and substantial doubt regarding its ability to continue as a going concern.

PAVmed reports Q1 2026 financial results, highlighting a $30 million Series D financing, debt restructuring, and continued commercialization efforts for its subsidiaries.

PAVmed Inc. reported a net loss for Q3 2025, facing a going concern warning while advancing subsidiary products and addressing Nasdaq compliance through a proposed reverse stock split.

PAVmed reports reduced operating losses and increased cash, driven by strategic restructuring and subsidiary financings, despite ongoing going concern doubts and Nasdaq compliance issues.

PAVmed Inc. reports a net income attributable to common stockholders of $17.7 million for Q1 2025, driven by fair value adjustments in equity method investments, while navigating liquidity challenges and strategic shifts.

PAVmed Inc. reported its third quarter 2024 results, marked by a significant gain from the deconsolidation of Lucid Diagnostics, but also ongoing operational losses and financial uncertainties.

PAVmed Inc. reported a net loss of $10.9 million for the second quarter of 2024, with revenue of $1.0 million, primarily driven by EsoGuard testing.

PAVmed Inc. has obtained a waiver for certain debt covenants and extended the maturity dates of its senior secured convertible notes, while reporting a net loss for the first quarter of 2024.